Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

911 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma.
Rossi N, Lee KA, Bermudez MV, Visconti A, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Newton-Bishop J, Harland M, Shaw HM, Harries M, Sacco J, Board R, Lorigan P, de Vries EGE, Segata N, Taams L, Papa S, Spector TD, Nathan P, Weersma RK, Hospers GAP, Fehrmann RSN, Bataille V, Falchi M. Rossi N, et al. Among authors: papa s. EBioMedicine. 2022 Sep;83:104235. doi: 10.1016/j.ebiom.2022.104235. Epub 2022 Aug 22. EBioMedicine. 2022. PMID: 36007304 Free PMC article.
Treatment for metastatic melanoma: a new and evolving era.
Sousa R, Cortes P, Harries M, Papa S. Sousa R, et al. Among authors: papa s. Int J Clin Pract. 2015 Mar;69(3):273-80. doi: 10.1111/ijcp.12583. Int J Clin Pract. 2015. PMID: 25727802 Review. No abstract available.
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.
Khair DO, Bax HJ, Mele S, Crescioli S, Pellizzari G, Khiabany A, Nakamura M, Harris RJ, French E, Hoffmann RM, Williams IP, Cheung A, Thair B, Beales CT, Touizer E, Signell AW, Tasnova NL, Spicer JF, Josephs DH, Geh JL, MacKenzie Ross A, Healy C, Papa S, Lacy KE, Karagiannis SN. Khair DO, et al. Among authors: papa s. Front Immunol. 2019 Mar 19;10:453. doi: 10.3389/fimmu.2019.00453. eCollection 2019. Front Immunol. 2019. PMID: 30941125 Free PMC article. Review.
IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states.
Pellizzari G, Hoskin C, Crescioli S, Mele S, Gotovina J, Chiaruttini G, Bianchini R, Ilieva K, Bax HJ, Papa S, Lacy KE, Jensen-Jarolim E, Tsoka S, Josephs DH, Spicer JF, Karagiannis SN. Pellizzari G, et al. Among authors: papa s. EBioMedicine. 2019 May;43:67-81. doi: 10.1016/j.ebiom.2019.03.080. Epub 2019 Apr 5. EBioMedicine. 2019. PMID: 30956175 Free PMC article.
Mechanisms of checkpoint inhibition-induced adverse events.
Urwyler P, Earnshaw I, Bermudez M, Perucha E, Wu W, Ryan S, Mcdonald L, Karagiannis SN, Taams LS, Powell N, Cope A, Papa S. Urwyler P, et al. Among authors: papa s. Clin Exp Immunol. 2020 May;200(2):141-154. doi: 10.1111/cei.13421. Epub 2020 Feb 21. Clin Exp Immunol. 2020. PMID: 31989585 Free PMC article. Review.
Impact of age on the toxicity of immune checkpoint inhibition.
Samani A, Zhang S, Spiers L, Suwaidan AA, Merrick S, Tippu Z, Payne M, Faust G, Papa S, Fields P, Van Hemelrijck M, Josephs DH. Samani A, et al. Among authors: papa s. J Immunother Cancer. 2020 Oct;8(2):e000871. doi: 10.1136/jitc-2020-000871. J Immunother Cancer. 2020. PMID: 33033183 Free PMC article.
Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.
Willsmore ZN, Coumbe BGT, Crescioli S, Reci S, Gupta A, Harris RJ, Chenoweth A, Chauhan J, Bax HJ, McCraw A, Cheung A, Osborn G, Hoffmann RM, Nakamura M, Laddach R, Geh JLC, MacKenzie-Ross A, Healy C, Tsoka S, Spicer JF, Josephs DH, Papa S, Lacy KE, Karagiannis SN. Willsmore ZN, et al. Among authors: papa s. Eur J Immunol. 2021 Mar;51(3):544-556. doi: 10.1002/eji.202048747. Epub 2021 Feb 23. Eur J Immunol. 2021. PMID: 33450785 Free article. Review.
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.
Willsmore ZN, Harris RJ, Crescioli S, Hussein K, Kakkassery H, Thapa D, Cheung A, Chauhan J, Bax HJ, Chenoweth A, Laddach R, Osborn G, McCraw A, Hoffmann RM, Nakamura M, Geh JL, MacKenzie-Ross A, Healy C, Tsoka S, Spicer JF, Papa S, Barber L, Lacy KE, Karagiannis SN. Willsmore ZN, et al. Among authors: papa s. Front Immunol. 2021 Jan 25;11:622442. doi: 10.3389/fimmu.2020.622442. eCollection 2020. Front Immunol. 2021. PMID: 33569063 Free PMC article. Review.
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab.
Alexander JL, Ibraheim H, Sheth B, Little J, Khan MS, Richards C, Hunter N, Chauhan D, Ratnakumaran R, McHugh K, Pinato DJ, Nathan P, Choy J, Crusz SM, Furness A, Turajlic S, Pickering L, Larkin J, Teare JP, Papa S, Speight A, Sharma A, Powell N. Alexander JL, et al. Among authors: papa s. J Immunother Cancer. 2021 Jul;9(7):e002742. doi: 10.1136/jitc-2021-002742. J Immunother Cancer. 2021. PMID: 34233964 Free PMC article.
911 results